Drugs / BCD-178
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05738993 | Aug 2022 → Apr 2023 | breast cancer | Biocad | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05802225 | Jan 2023 → Jun 2025 overdue | breast cancer | Biocad | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-178 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05802225 ↗ |
| Route | Intravenous | “A single intravenous (IV) infusion at a dose of 420 mg” NCT05738993 ↗ |